Risk Factors for Readmission Within One Year After Acute Exacerbations of Bronchiectasis in a Chinese Tertiary Hospital: a Retrospective Cohort Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Dec 19

PMID 39695551

Authors

Yaxin Fan

Ben Su

Huiyong Zhang

Xiaoyu Yang

Zhengyi Zhang

Shaoyan Zhang

Shunxian Zhang

Dingzhong Wu

Peiyong Zheng

Zhenhui Lu

Lei Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Frequent exacerbations of bronchiectasis lead to poor quality of life, impaired lung function, and higher mortality rates. This study aims to evaluate the risk factors associated with readmission within one year due to acute exacerbation of bronchiectasis (AEB).

Methods: A retrospective cohort study was performed on 260 patients with bronchiectasis who were hospitalized in the respiratory and critical care department of a tertiary hospital in China. Univariate and multivariate Cox analyses were used to evaluate the risk factors for readmission within one year.

Results: Readmission within one year was found in 44.6% of 260 patients hospitalized with acute exacerbation of bronchiectasis. The risk factors associated with readmission included age over 65 years (HR = 3.66; 95% CI: 2.30 to 5.85), BMI < 18.5 kg/m (HR = 1.71; 95% CI: 1.16 to 2.51), respiratory intensive care unit (RICU) stay during admission (HR = 2.06, 95% CI: 1.16-3.67), involvement of 3 or more lobes on chest high-resolution computed tomography (HRCT) (HR = 1.85; 95% CI, 1.22 to 2.80), chronic Pseudomonas aeruginosa (PA) colonization (HR = 2.29; 95% CI: 1.54 to 3.38), and positive sputum culture results within 24 h after admission (HR = 1.93; 95% CI: 1.27 to 2.94). Long-term oral antibiotics use after discharge was associated with decreased hazard of readmission (HR = 0.34; 95% CI: 0.20 to 0.59).

Conclusions: Patients with bronchiectasis have a high rate of readmission, which is linked to varieties of risk factors, and identifying these risk factors is importance for effectively managing patients with bronchiectasis.

References

ODonnell A . Bronchiectasis - A Clinical Review. N Engl J Med. 2022; 387(6):533-545. DOI: 10.1056/NEJMra2202819. View

Tunney M, Einarsson G, Wei L, Drain M, Klem E, Cardwell C . Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013; 187(10):1118-26. PMC: 3734618. DOI: 10.1164/rccm.201210-1937OC. View

Barker A . Bronchiectasis. N Engl J Med. 2002; 346(18):1383-93. DOI: 10.1056/NEJMra012519. View

Polverino E, Goeminne P, McDonnell M, Aliberti S, Marshall S, Loebinger M . European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00629-2017. View

Hill A, Sullivan A, Chalmers J, Soyza A, Elborn S, Floto A . British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2018; 74(Suppl 1):1-69. DOI: 10.1136/thoraxjnl-2018-212463. View

Wang J, Chen X, He S, Li J, Ma T, Liu L . COPD Assessment Test and risk of readmission in patients with bronchiectasis: a prospective cohort study. ERJ Open Res. 2024; 10(2). PMC: 10945388. DOI: 10.1183/23120541.00867-2023. View

Ringshausen F, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J . Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015; 46(6):1805-7. DOI: 10.1183/13993003.00954-2015. View

Wang X, Li R, Wang W, Li D, Zhou Y, Chen X . Bronchiectasis severity assessment on predicting hospital readmission: a single-center prospective cohort study. Chin Med J (Engl). 2020; 134(4):492-494. PMC: 7909381. DOI: 10.1097/CM9.0000000000001051. View

Lee J, Lee S, Han C, Lee S, Kim C, Lee S . Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study. Respir Med. 2021; 180:106370. DOI: 10.1016/j.rmed.2021.106370. View

10.

Haworth C, Floto R . Antibiotic Management in Bronchiectasis. Clin Chest Med. 2022; 43(1):165-177. DOI: 10.1016/j.ccm.2021.11.009. View

11.

Monteagudo M, Rodriguez-Blanco T, Barrecheguren M, Simonet P, Miravitlles M . Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. Respir Med. 2016; 121:26-31. DOI: 10.1016/j.rmed.2016.10.014. View

12.

Finch S, McDonnell M, Abo-Leyah H, Aliberti S, Chalmers J . A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann Am Thorac Soc. 2015; 12(11):1602-11. DOI: 10.1513/AnnalsATS.201506-333OC. View

13.

Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H . Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):660-7. DOI: 10.1016/S0140-6736(12)60953-2. View

14.

Araujo D, Shteinberg M, Aliberti S, Goeminne P, Hill A, Fardon T . The independent contribution of infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.01953-2017. View

15.

Diel R, Ewig S, Blaas S, Jacob C, Juelich F, Korfmann G . Incidence of patients with non-cystic fibrosis bronchiectasis in Germany - A healthcare insurance claims data analysis. Respir Med. 2019; 151:121-127. DOI: 10.1016/j.rmed.2019.04.007. View

16.

Quittner A, ODonnell A, Salathe M, Lewis S, Li X, Montgomery A . Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2014; 70(1):12-20. DOI: 10.1136/thoraxjnl-2014-205918. View

17.

Dicker A, Lonergan M, Keir H, Smith A, Pollock J, Finch S . The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respir Med. 2021; 9(8):885-896. DOI: 10.1016/S2213-2600(20)30557-9. View

18.

Conceicao M, Shteinberg M, Goeminne P, Altenburg J, Chalmers J . Eradication treatment for infection in adults with bronchiectasis: a systematic review and meta-analysis. Eur Respir Rev. 2024; 33(171). PMC: 10828832. DOI: 10.1183/16000617.0178-2023. View

19.

Chandrasekaran R, Mac Aogain M, Chalmers J, Elborn S, Chotirmall S . Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018; 18(1):83. PMC: 5964678. DOI: 10.1186/s12890-018-0638-0. View

20.

Weycker D, Hansen G, Seifer F . Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017; 14(4):377-384. PMC: 5729734. DOI: 10.1177/1479972317709649. View